Federal Register / Vol. 72, No. 133 / Thursday, July 12, 2007 / Notices 38089 

suppressor Caliban/Sdccag1 gene 

product is functioning in cells. 

Advantages: Caliban/Sdccag1 can be 

easily adopted into already standard 

gene therapy applications; Provides a 

novel therapeutic and diagnostic target 

for cancer. 

Benefits: It is estimated that there will 

be approximately 160,000 deaths caused 

by lung cancer in 2007. This technology 

will help in improving the quality of life 

of lung cancer patients as well as other 

cancers. Additionally, the gene therapy 

market is now a multi-million dollar 

industry. 

Inventors: Mark A. Mortin (NICHD), 

Xiaolin Bi (NCI). 

U.S. Patent Status: Pending PCT 

Application PCT/US2006/022180, 

published as WO 2006/13316 (E–118–

2005/0–PCT–02). 

Licensing Contact: David A. 

Lambertson, Ph.D.; Phone: (301) 435–

4632; Fax: (301) 402–0220; E-mail: 

lambertsond@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Child Health 

and Human Development is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to obtain pre-clinical data to be 

used to further develop, evaluate, or 

commercialize Caliban/Sdccag1 as a 

novel therapeutic and diagnostic target 

for cancer and other diseases. Please 

contact John D. Hewes, Ph.D. at 301–

435–3121 or hewesj@mail.nih.gov for 

more information. 

Dated: July 5, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–13542 Filed 7–11–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel, GWA Phenotype and Exposure 

Measures. 

Date: July 19, 2007. 

Time: 12 p.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Suite 4076, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Ken D. Nakamura, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, National Human Genome 

Research Institute, National Institutes of 

Health, 5635 Fishers Lane, Suite 4076, MSC 

9306, Rockville, MD 20852, 301–402–0838, 

nakamurk@mail.nih.gov. 

This note is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: July 6, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3397 Filed 7–11–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Disorders; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The purpose of this 

meeting is to evaluate requests for 

preclinical development resources for 

potential new therapeutics for type 1 

diabetes. The outcome of the evaluation 

will be a decision whether NIDDK 

should support the request and make 

available contract resources for 

development of the potential 

therapeutic to improve the treatment or 

prevent the development of type 1 

diabetes and its complications. The 

research proposals and the discussions 

could disclose confidential trade secrets 

or commercial property such as 

patentable material, and personal 

information concerning individuals 

associated with the proposed research 

projects, the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Type 1 Diabetes—

Rapid Access to Intervention Development 

Special Emphasis Panel, National Institute of 

Diabetes and Digestive and Kidney Diseases. 

Date: July 31, 2007. 

Time: 12 p.m. to 2 p.m. 

Agenda: To evaluate requests for 

preclinical development resources for 

potential new therapeutics for type 1 diabetes 

and its complications. 

Place: 6707 Democracy Boulevard, 

Bethesda, MD 20892 (Telephone Conference 

Call). 

Contact Person: Dr. Lisa Spain, Program 

Director, Immunobiology of Type 1 Diabetes 

and Autoimmune Endocrine Diseases, 

Division of Diabetes, Endocrinology and 

Metabolic Diseases, NIDDK, NIH, 6707 

Democracy Boulevard, Bethesda, MD 20892–

5460, 301–451–9871. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 98.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: July 3, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3401 Filed 7–11–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel, Scientific Research Analysis 

in Bioinformatics and Allied Areas. 


rwilkins on PROD1PC63 with NOTICES